Management of alcohol use disorder: a gastroenterology and hepatology-focused perspective

IF 38.6 1区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Lancet Gastroenterology & Hepatology Pub Date : 2025-02-13 DOI:10.1016/s2468-1253(24)00380-7
Luis Antonio Díaz, Daniel König, Sabine Weber, Gustavo Ayares, José Miguel Fuentealba, Valeria Vázquez, Ramon Bataller, Patrick S Kamath, Gerald Scott Winder, Lorenzo Leggio, Juan Pablo Arab
{"title":"Management of alcohol use disorder: a gastroenterology and hepatology-focused perspective","authors":"Luis Antonio Díaz, Daniel König, Sabine Weber, Gustavo Ayares, José Miguel Fuentealba, Valeria Vázquez, Ramon Bataller, Patrick S Kamath, Gerald Scott Winder, Lorenzo Leggio, Juan Pablo Arab","doi":"10.1016/s2468-1253(24)00380-7","DOIUrl":null,"url":null,"abstract":"Alcohol use disorder is a prevalent and major but preventable cause of morbidity and mortality worldwide, causing several important health consequences, including chronic liver disease. Despite its substantial effects, most clinicians do not adequately assess alcohol intake in clinical practice, and there are several barriers to providing integrated management to patients with alcohol use disorder. Standardised questionnaires, such as the Alcohol Use Identification Test (AUDIT), can facilitate the identification of individuals at risk of alcohol use disorder, and alcohol biomarkers such as phosphatidylethanol aid in quantifying levels of alcohol consumption. Non-pharmacological interventions—including brief interventions, twelve-step facilitation, motivational enhancement therapy, contingency management, and cognitive behavioural therapy—are effective for patients with alcohol use disorder, regardless of the presence of advanced liver disease. Pharmacological treatments should be considered according to the severity of liver disease and other comorbidities, safety profile, and local availability. The management of patients with alcohol use disorder and associated liver disease should ideally be performed in the setting of integrated multidisciplinary teams.","PeriodicalId":56028,"journal":{"name":"Lancet Gastroenterology & Hepatology","volume":"79 1","pages":""},"PeriodicalIF":38.6000,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Lancet Gastroenterology & Hepatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/s2468-1253(24)00380-7","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Alcohol use disorder is a prevalent and major but preventable cause of morbidity and mortality worldwide, causing several important health consequences, including chronic liver disease. Despite its substantial effects, most clinicians do not adequately assess alcohol intake in clinical practice, and there are several barriers to providing integrated management to patients with alcohol use disorder. Standardised questionnaires, such as the Alcohol Use Identification Test (AUDIT), can facilitate the identification of individuals at risk of alcohol use disorder, and alcohol biomarkers such as phosphatidylethanol aid in quantifying levels of alcohol consumption. Non-pharmacological interventions—including brief interventions, twelve-step facilitation, motivational enhancement therapy, contingency management, and cognitive behavioural therapy—are effective for patients with alcohol use disorder, regardless of the presence of advanced liver disease. Pharmacological treatments should be considered according to the severity of liver disease and other comorbidities, safety profile, and local availability. The management of patients with alcohol use disorder and associated liver disease should ideally be performed in the setting of integrated multidisciplinary teams.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
酒精使用障碍的管理:以胃肠病学和肝病学为重点的观点
酒精使用障碍是全世界发病率和死亡率的一个普遍和主要但可预防的原因,造成包括慢性肝病在内的若干重要健康后果。尽管酒精有很大的影响,但大多数临床医生在临床实践中没有充分评估酒精摄入,并且在为酒精使用障碍患者提供综合管理方面存在一些障碍。标准化问卷,如酒精使用识别测试(审核),可以促进识别有酒精使用障碍风险的个人,酒精生物标志物,如磷脂酰乙醇,有助于量化酒精消费水平。非药物干预——包括简短干预、十二步促进、动机增强疗法、应急管理和认知行为疗法——对酒精使用障碍患者有效,无论是否存在晚期肝病。应根据肝脏疾病和其他合并症的严重程度、安全性和当地可用性来考虑药物治疗。酒精使用障碍及相关肝脏疾病患者的管理最好在多学科综合团队中进行。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
50.30
自引率
1.10%
发文量
0
期刊介绍: The Lancet Gastroenterology & Hepatology is an authoritative forum for key opinion leaders across medicine, government, and health systems to influence clinical practice, explore global policy, and inform constructive, positive change worldwide. The Lancet Gastroenterology & Hepatology publishes papers that reflect the rich variety of ongoing clinical research in these fields, especially in the areas of inflammatory bowel diseases, NAFLD and NASH, functional gastrointestinal disorders, digestive cancers, and viral hepatitis.
期刊最新文献
Transanal total mesorectal excision in the era of robotic surgery Long-term progression of steatotic liver disease: multiple drivers of the same disease? Binge drinking, metabolic dysfunction, and the spectrum of steatotic liver disease in the USA: a cross-sectional and longitudinal analysis Transanal total mesorectal excision versus laparoscopic total mesorectal excision for mid and low rectal cancer (COLOR III): short-term outcomes of an international, multicentre, phase 3, randomised, controlled, non-inferiority trial Indocyanine green works: redefining research priorities in colorectal surgery
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1